您现在的位置是:weatherly funeral home in york alabama > Entertainment
【who lives at 100 north carolwood drive】EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Tops Revenue Estimates
weatherly funeral home in york alabama2024-09-29 12:21:55【Entertainment】6人已围观
简介EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.09 per share versus the Zacks C who lives at 100 north carolwood drive
EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.12. This who lives at 100 north carolwood drivecompares to loss of $0.12 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 25%. A quarter ago, it was expected that this drug delivery technology company would post a loss of $0.14 per share when it actually produced a loss of $0.14, delivering no surprise.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
EyePoint Pharmaceuticals, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $8.63 million for the quarter ended December 2019, surpassing the Zacks Consensus Estimate by 12.19%. This compares to year-ago revenues of $2.44 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
EyePoint Pharmaceuticals shares have lost about 7.1% since the beginning of the year versus the S&P 500's decline of -3.1%.
What's Next for EyePoint Pharmaceuticals?
While EyePoint Pharmaceuticals has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for EyePoint Pharmaceuticals was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Story continues
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.11 on $8.73 million in revenues for the coming quarter and -$0.32 on $48.32 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
EYEPOINT PHARMACEUTICALS, INC. (EYPT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
View comments
很赞哦!(254)
相关文章
- Orkla ASA: Higher in-home consumption of food and cleaning products spurred growth for Orkla
- Paul Weiss, Partner Promotions and the Path to Diversity in Big Law
- See which colours dominated your Instagram posts in 2018
- Paul Weiss, Partner Promotions and the Path to Diversity in Big Law
- Expanse Integrates with ServiceNow
- Implied Volatility Surging for Franklin Street (FSP) Stock Options
- Zacks Rank #5 Additions for Monday
- Nigeria's Kaduna refinery expected to resume by mid-April - NNPC
- Plug Power (PLUG) to Report Q4 Earnings: What to Expect?
- BRIEF-Palm Eco-Town's Unit Signs Agreement On Property Project Worth 6.6 Bln Yuan In Hainan
热门文章
站长推荐
This Day In Market History: Buffett's $3B GE Bet
Italian 10-yr yield hits 3-1/2 month low after lawmakers endorse budget deal
Kristen Wiig and Ben Affleck to host 'Saturday Night Live'
Mitt Romney to visit 'Live With Kelly'
Nio Deliveries Jump 109% In November, Boosts Production Capacity To Keep Pace With Rising Demand
EUR/USD Price Forecast – EURO Declines On Dovish Outlook
AP, News Media Guild reach new tentative 3 ½ year agreement
‘The Bear’ Fans Notice a Potential Continuity Error During Tina’s Backstory Episode in Season 3
友情链接
- How Much Are MTY Food Group Inc. (TSE:MTY) Insiders Taking Off The Table?
- BRIEF-Hainan Yatai Industrial Plans To Buy 70 Pct Stake In Synthesis Med Chem (Hong Kong)
- The Latest: Utility: Wildfire role would implicate probation
- Pay Up?, Clear as Mud, ‘Excellent’ Schools: The Morning Minute
- Should You Investigate Grupo Ezentis S.A. (BME:EZE) At €0.48?
- Enterprise Products: 2Q Earnings Snapshot
- Google wins U.S. approval for radar-based hand motion sensor
- Crocs, Shoe Carnival Surge Higher After Susquehanna Upgrades
- Walmart is cutting thousands of its highest-paying jobs
- China denies diplomat spied on Japan